Skip to main content
Premium Trial:

Request an Annual Quote

NuProbe VarTrace Sanger Assays

NuProbe Global has launched VarTrace Sanger assays for ultrasensitive detection and quantification of cancer mutations with variant allele frequencies down to 0.1 percent. The company specifically launched three assays covering EGFR mutations for non-small-cell lung cancer; BRAF mutations for melanoma and thyroid cancer; and FLT3, DNMT3A, IDH1, IDH2, KIT, NPM1 mutations for acute myeloid leukemia. The assays are based on the firm's proprietary blocker displacement amplification (BDA) technology, and are compatible with both cell-free DNA from blood plasma and tissue samples including formalin-fixed paraffin-embedded tissue, NuProbe said.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.